Prescriber specialty is the strongest factor associated with dabigatran versus warfarin use. Here, the panelists discuss why the novel oral anticoagulants may not be popular among primary care physicians and talk about how to get primary care on board with newer therapeutic options.
Even though the guidelines recommend physicians monitor creatinine clearance once a year, the experts say that may not be frequently enough. In this segment, the panelists discuss how frequently to monitor renal function when using the novel oral anticoagulants.
Researcher report that higher levels of neuronal activity are associated with increased production of myelin in animal models – a finding which may eventually help the development of multiple sclerosis therapies.